A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Diffuse Cutaneous Systemic Sclerosis Spiera, R. F., Hummers, L. K., Chung, L., Frech, T. M., Domsic, R. T., Hsu, V., Furst, D. E., Gordon, J. K., Mayes, M. D., Simms, R. W., Constantine, S., White, B. WILEY. 2017

View details for Web of Science ID 000411824106388